trending Market Intelligence /marketintelligence/en/news-insights/trending/h16nzdetgbbhamz8agmp2w2 content esgSubNav
In This List

Ekso Bionics names CEO, replaces director

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Ekso Bionics names CEO, replaces director

Ekso Bionics Holdings Inc. appointed Jack Peurach as president and CEO, effective March 9.

Peurach succeeds Thomas Looby, who is leaving the company and the board to pursue other interests.

Peurach, who is a co-founder of the company, will remain on the board where he has been since January 2011. He was the executive vice president of products for SunPower Corp. before joining Ekso.

Richmond, Calif.-based Ekso Bionics also said that Howard Palefsky and Amy Wendell stepped down from the board, also effective March 9.

Charles Li, a senior analyst at Puissance Capital Management, has joined the board, effective March 11.

Ekso Bionics is a developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance, and mobility across medical and industrial applications.